52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Mease, Philip [1 ,2 ]
Okada, Masan [3 ]
Kishimoto, Mitsumasa [4 ]
Shuler, Catherine [5 ]
Carlier, Hilde [5 ]
Lin, Chen-Yen [5 ]
Mou, Jiani [5 ]
Moriarty, Susan [5 ]
Lee, Chin [5 ]
Gladman, Dafna [6 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] St Lukes Int Hosp, Tokyo, Japan
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
176
引用
收藏
页码：925 / 925
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
    van der Heijde, Desiree
    Gladman, Dafna D.
    Kishimoto, Mitsumasa
    Okada, Masato
    Rathmann, Suchitrita S.
    Moriarty, Susan R.
    Shuler, Catherine L.
    Carlier, Hilde
    Benichou, Olivier
    Mease, Philip J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (03) : 367 - 377
  • [2] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [3] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) (vol 45, pg 367, 2018)
    Van der Heijde, D.
    Gladman, D. D.
    Kishimoto, M.
    Okada, M.
    Rathmann, S. S.
    Moriarty, S. R.
    Shuler, C. L.
    Carlier, H.
    Benichou, O.
    Mease, P. J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (11) : 1608 - 1608
  • [4] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 52 IN BIOLOGIC NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (SPIRIT-P1)
    Lespessailles, Eric
    Kirkham, Bruce
    Nebro, Antonio Fernandez
    Blanco, Ricardo
    Strehblow, Christoph
    Inciarte-Mundo, Jose
    Porsdal, Vibeke
    Garcia, Miriam
    Kurzawa, Monika
    Sapin, Christophe
    Geusens, Piet
    Goupille, Philippe
    Tahir, Hasan
    RHEUMATOLOGY, 2018, 57
  • [5] Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C.
    Mou, J.
    Moriarty, S. R.
    Lee, C.
    Gladman, D.
    Satler, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [6] Fifty two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S.
    Lee, C.
    Gladman, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 33
  • [7] Efficacy and safety of ixekizumab at week 52 in biologic-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Lespessailles, E.
    Kirkham, B.
    Nebro, A.
    Alonso, R.
    Strehblow, C.
    Inciarte, J.
    Porsdal, V.
    Garcia, M.
    Kurzawa, M.
    Sapin, C.
    Geusens, P.
    Goupille, P.
    Tahir, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 44 - 45
  • [8] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 23 - 24
  • [9] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 845
  • [10] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, V.
    Fleischmann, R.
    Lespessailles, E.
    Helliwell, P. S.
    Benichou, O.
    Erickson, J.
    Shuler, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 385 - 385
12345